Cubist Systematic Strategies, LLC Alkermes Plc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $11.3 Million - $14 Million	429,823 New	429,823 $11.6 Million
Q3 2023 Nov 14, 2023	SELL	$27.17 - $31.97 $8.64 Million - $10.2 Million	-317,970 Reduced 64.46%	175,281 $4.91 Million
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $3.8 Million - $4.51 Million	134,255 Added 37.4%	493,251 $15.4 Million
Q1 2023 May 15, 2023	BUY	$25.31 - $29.02 $4.34 Million - $4.98 Million	171,519 Added 91.49%	358,996 $10.1 Million
Q4 2022 Feb 14, 2023	SELL	$21.94 - $26.24 $3.46 Million - $4.14 Million	-157,663 Reduced 45.68%	187,477 $4.9 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $106,568 - $154,378	4,844 Added 1.42%	345,140 $7.71 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $6.87 Million - $7.95 Million	260,416 Added 326.01%	340,296 $10.1 Million
Q1 2022 May 16, 2022	SELL	$23.07 - $27.99 $577,926 - $701,177	-25,051 Reduced 23.87%	79,880 $2.1 Million
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $978,452 - $1.46 Million	-45,573 Reduced 30.28%	104,931 $2.44 Million
Q3 2021 Nov 15, 2021	SELL	$23.37 - $32.13 $1.59 Million - $2.19 Million	-68,178 Reduced 31.18%	150,504 $4.64 Million
Q2 2021 Aug 16, 2021	BUY	$18.78 - $25.15 $506,966 - $678,924	26,995 Added 14.08%	218,682 $5.36 Million
Q1 2021 May 17, 2021	SELL	$18.21 - $23.2 $2.16 Million - $2.75 Million	-118,734 Reduced 38.25%	191,687 $3.58 Million
Q4 2020 Feb 16, 2021	BUY	$15.39 - $22.1 $3.5 Million - $5.02 Million	227,288 Added 273.4%	310,421 $6.19 Million
Q3 2020 Nov 16, 2020	SELL	$16.16 - $20.66 $101,727 - $130,054	-6,295 Reduced 7.04%	83,133 $1.38 Million
Q2 2020 Aug 14, 2020	SELL	$13.31 - $19.41 $2.49 Million - $3.62 Million	-186,734 Reduced 67.62%	89,428 $1.74 Million
Q1 2020 May 15, 2020	BUY	$13.06 - $21.24 $1 Million - $1.63 Million	76,858 Added 38.56%	276,162 $3.98 Million
Q4 2019 Feb 14, 2020	BUY	$17.29 - $21.74 $2.79 Million - $3.51 Million	161,571 Added 428.2%	199,304 $4.07 Million
Q3 2019 Nov 14, 2019	SELL	$19.51 - $24.28 $2.05 Million - $2.55 Million	-104,838 Reduced 73.53%	37,733 $736,000
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $2.02 Million - $3.51 Million	94,128 Added 194.31%	142,571 $3.21 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $36.49 $606,624 - $779,426	21,360 Added 78.87%	48,443 $1.77 Million
Q4 2018 Feb 14, 2019	BUY	$27.94 - $44.61 $756,699 - $1.21 Million	27,083 New	27,083 $799,000
Q2 2018 Aug 14, 2018	SELL	$40.56 - $51.36 $89,110 - $112,837	-2,197 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$53.61 - $67.26 $134,721 - $169,024	-2,513 Reduced 53.35%	2,197 $127,000
Q4 2017 Feb 14, 2018	SELL	$47.69 - $55.39 $386,145 - $448,492	-8,097 Reduced 63.22%	4,710 $258,000
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $629,592 - $697,341	12,807	12,807 $651,000

Others Institutions Holding ALKS

# of Institutions

362

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

Black Rock Inc. New York, NY

29.1M
Shares

$911 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$594 Million
0.01% of portfolio
Price T Rowe Associates Inc Baltimore, MD

13M
Shares

$407 Million
0.04% of portfolio
Wellington Management Group LLP Boston, MA

12.7M
Shares

$396 Million
0.06% of portfolio
State Street Corp Boston, MA

9.19M
Shares

$288 Million
0.01% of portfolio

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.14B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account